9966.HK
Price:
$11.22
Market Cap:
$9.83B
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast can...[Read more]
Industry
Biotechnology
IPO Date
2019-12-12
Stock Exchange
HKSE
Ticker
9966.HK
According to Alphamab Oncology’s latest financial reports and current stock price. The company's current PE Ratio is 41.56. This represents a change of 203.63% compared to the average of 13.69 of the last 4 quarters.
The mean historical PE Ratio of Alphamab Oncology over the last ten years is -59.19. The current 41.56 PE Ratio has changed -7121.81% with respect to the historical average. Over the past ten years (40 quarters), 9966.HK's PE Ratio was at its highest in in the June 2025 quarter at 70.01. The PE Ratio was at its lowest in in the January 2017 quarter at -165.47.
Average
-59.19
Median
-26.92
Minimum
-304.86
Maximum
19.34
Discovering the peaks and valleys of Alphamab Oncology PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 274.70%
Maximum Annual PE Ratio = 19.34
Minimum Annual Increase = -172.70%
Minimum Annual PE Ratio = -304.86
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 19.34 | -172.70% |
| 2023 | -26.60 | -2.38% |
| 2022 | -27.25 | 8.45% |
| 2021 | -25.12 | -16.43% |
| 2020 | -30.06 | 274.70% |
| 2019 | -8.02 | -88.69% |
| 2018 | -70.92 | -76.74% |
The current PE Ratio of Alphamab Oncology (9966.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-11.50
5-year avg
-17.94
10-year avg
-59.19
Alphamab Oncology’s PE Ratio is greater than HBM Holdings Limited (35.68), less than Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (76.68), greater than Shanghai Haohai Biological Technology Co., Ltd. (26.65), less than Nanjing Leads Biolabs Co Ltd (0), less than Abbisko Cayman Limited (51.40), greater than Lepu Biopharma Co., Ltd. (-57.83), greater than CARsgen Therapeutics Holdings Limited (-18.98), greater than Beijing Chunlizhengda Medical Instruments Co., Ltd. (35.92), greater than CStone Pharmaceuticals (-28.07), greater than Ascletis Pharma Inc. (-42.10),
| Company | PE Ratio | Market cap |
|---|---|---|
| 35.68 | $10.38B | |
| 76.68 | $11.30B | |
| 26.65 | $10.28B | |
| 0 | $9.85B | |
| 51.40 | $8.74B | |
| -57.83 | $9.80B | |
| -18.98 | $8.39B | |
| 35.92 | $9.16B | |
| -28.07 | $8.53B | |
| -42.10 | $12.05B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alphamab Oncology using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alphamab Oncology or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Alphamab Oncology's PE Ratio?
How is the PE Ratio calculated for Alphamab Oncology (9966.HK)?
What is the highest PE Ratio for Alphamab Oncology (9966.HK)?
What is the 3-year average PE Ratio for Alphamab Oncology (9966.HK)?
What is the 5-year average PE Ratio for Alphamab Oncology (9966.HK)?
How does the current PE Ratio for Alphamab Oncology (9966.HK) compare to its historical average?